Advocacy intelligence hub — real-time data for patient organizations
University of Michigan
Recorlev: FDA approved
Treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative
Korlym: FDA approved
for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Mifepristone
Danco
Patient Assistance Programs2
Recorlev
Strongbridge Dublin Limited
Korlym
Corcept Therapeutics, Inc.
Recorlev
(levoketoconazole)Orphan drugStrongbridge Dublin Limited
Cortisol Synthesis Inhibitor [EPC]
Korlym
(mifepristone)Orphan drugCorcept Therapeutics, Inc.
Progestin Antagonist [EPC]
12.1 Mechanism of Action Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-I...
Andreas Moraitis, MD, M.D
Corcept Therapeutics
📍 SUNNY ISLES BEACH, FL
Ying Ru, MD, PhD
Corcept Therapeutics
Coleman Gross, MD
Corcept Therapeutics
📍 MCMINNVILLE, OR
Andreas G Moraitis, MD, M.D
Corcept Therapeutics
📍 SUNNY ISLES BEACH, FL
Coleman Gross, M.D., MD
Corcept Therapeutics
📍 MCMINNVILLE, OR
Xavier Valencia, MD
Cortendo AB
📍 DEERFIELD BEACH, FL